The imaging viewpoint: how imaging affects determination of progression-free survival.

dc.contributor.author

Sullivan, Daniel Carl

dc.contributor.author

Schwartz, Lawrence H

dc.contributor.author

Zhao, Binsheng

dc.coverage.spatial

United States

dc.date.accessioned

2015-12-06T15:23:39Z

dc.date.issued

2013-05-15

dc.description.abstract

Tumor measurements on computed tomgoraphic or MRI scans and/or the appearance of new lesions on any of a variety of imaging studies including positron emission tomographic scans are key determinants for assessing progression-free survival as an endpoint in many clinical trials of therapies for solid tumors. Test-retest tumor measurement reproducibility may vary considerably across serial scans on the same patient unless rigorous attention is paid to standardization of image acquisition parameters and unless measurements are made by trained, experienced observers using validated objective methods. Target lesion selection also must be done with care to choose lesions that are or will be reproducibly measurable. Likewise, new lesions will be missed or misinterpreted on follow-up imaging studies unless those imaging studies are obtained using techniques suitable for detecting early, small lesions. Reader variability is clearly a major component of the problem. The increasing availability of semiautomatic image processing algorithms will help ameliorate that issue. In addition, an array of internationally accepted guidelines, standards, and accreditation programs now exist to help address these problems.

dc.identifier

http://www.ncbi.nlm.nih.gov/pubmed/23669422

dc.identifier

19/10/2621

dc.identifier.issn

1078-0432

dc.identifier.uri

https://hdl.handle.net/10161/11100

dc.language

eng

dc.publisher

American Association for Cancer Research (AACR)

dc.relation.ispartof

Clin Cancer Res

dc.relation.isversionof

10.1158/1078-0432.CCR-12-2936

dc.subject

Diagnostic Imaging

dc.subject

Disease-Free Survival

dc.subject

Endpoint Determination

dc.subject

Follow-Up Studies

dc.subject

Humans

dc.subject

Neoplasms

dc.subject

Radiography

dc.subject

Radionuclide Imaging

dc.subject

Reproducibility of Results

dc.subject

Treatment Outcome

dc.title

The imaging viewpoint: how imaging affects determination of progression-free survival.

dc.type

Journal article

duke.contributor.orcid

Sullivan, Daniel Carl|0000-0002-7556-5650

pubs.author-url

http://www.ncbi.nlm.nih.gov/pubmed/23669422

pubs.begin-page

2621

pubs.end-page

2628

pubs.issue

10

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

Duke Clinical Research Institute

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Radiology

pubs.organisational-group

School of Medicine

pubs.publication-status

Published

pubs.volume

19

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Clin Cancer Res-2013-Sullivan-2621-8.pdf
Size:
3.45 MB
Format:
Adobe Portable Document Format
Description:
Published version